期刊文献+

分泌型人胸腺素α_1基因工程菌高密度发酵工艺的研究 被引量:1

Study on high cell density fermentation of secretory recombinant human thymosin alpha 1
在线阅读 下载PDF
导出
摘要 探索分泌型重组人胸腺素1α工程菌的高密度高表达发酵工艺.在摇瓶培养获得大肠杆菌分泌型重组人胸腺素1α融合蛋白发酵的最佳条件的基础上,用15 L自控发酵罐进行分批补料培养,发酵中分阶段限制性流加氮、碳源,保持溶氧在30%以上,OD600约为25的时候,添加0.5 mmol/LIPTG于28℃诱导10 h.最终菌体密度OD600可达40以上,目的产物占菌体总蛋白25%以上.分泌型人胸腺素1α基因工程菌高密度发酵工艺的建立为工业化生产重组人胸腺素1α提供基础. To research the high cell density and high-expression fermentation of secretory recombinant human thymosin α1, the fed-batch fermentation was carried out in 15 L automatic fermentor on the basis of the optimized culture conditions obtained from the process of flask shaking culture. During the process of fermentation, nitrogen and carbohydrate were controlled at a special speed. The dissolved oxygen was maintained around 30%. And the induction started as OD600 reached about 25 by adding IPTG to a final concentration of 0.5 mmol/L and then continued incubation 10 hours at 28℃. The final cell density (OD600) exceeded 40, and the recombinant protein expression level was over 25% of the total cellular protein. The study provides a basis for largescale production of human thymosin α1 in industrial fermentation.
出处 《浙江工业大学学报》 CAS 2006年第3期277-280,共4页 Journal of Zhejiang University of Technology
基金 浙江省科技厅资助项目(No.2005C33031)
关键词 高密度发酵 胸腺素Α1 大肠杆菌 表达 high cell density fermentation thymosin α1 E. coli expression
  • 相关文献

参考文献13

  • 1LOW T L,GOLDSTEIN A.The chemistry and biology of thymosin Ⅰ:Amino acid sequence of thymosin alpha 1 and polypeptide beta[J].Biol Chem,1979,254(3):987-995.
  • 2MICHALEWSHY J,GABRIEL I F,WINTER D P,et al.Confirmation of the primary structure of thymosin alpha1 by microsequence analysis of limited acid and enzymatic hydrolysis fragments[J].Int J Pept Protein Rcs,1983,21 (1):93-99.
  • 3AMARAPURKAR D,DAS H S.Thymosin alpha in the treatment of chronic hepatitis B:an uncontrolled open-label trial[J].Indian J Gastroenterol,2002,21(2):59-61.
  • 4LAU G K,NANJI A,HOU J,et al.Thymosin-alpha 1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase[J].Viral Hepat,2002,9 (4):280-287.
  • 5ANDREONE P,CURSARO C,GRAMENZI A,et al.In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C[J].J Viral Hepat,2001,8:194-201.
  • 6MOSACRELLA S,BUZZELLI G,ROMANELLI R G,et al.Interferon and thymosin combination therapy in naive patients with chronic hepatitis C:prelim inary results[J].Liver,1998,18(5):366-369.
  • 7SILECCHIA G,GUARINO E,SINIBADI V P,et al.Efficacy of repeated cycles of chemoimmunotherapy with thymosin alpha l and interleukin-2 after intraperitoneal 5-fluorouracil delivery[J].Cancer Immunol Immunother,1999,48 (4):172-178.
  • 8ENRICO G,FRANCESCA P,PAOLA S V,et al.Thymosin α1 in combination with cytokines and chemotherapy for the treatment of cancer[J].International Immunopharmacology,2003,3(8):1145-1150.
  • 9ENRICO G,FRANCESCA P,GUIDO R,et al.Thymosin alpha 1 in the treatment of cancer:from basic research to clinical application[J].International Journal of Immunopharmacology,2000,22(12):1067-1076.
  • 10GARACI E,ROCCHI G,PERRONI L,et al.Combination treatment with zidovudine,thymoain alpha 1 and interferonalpha in human immunodeficiency virus infection[J].Int J Clin Lab Res,1994,24(1):23-28.

二级参考文献15

  • 1Low T L, Goldstein A. The chemistry and biology of thymosin Ⅰ : amino acid sequence of thymosin alpha 1 and polypeptide beta[J]. Biol. Chem, 1979,254(3): 987-995.
  • 2Michalewshy J, Gabriel I F, Winter D P,et al. Confirmation of the primary structure of thymosin alpha1 by microsequence analysis of limited acid and enzymatic hydrolysis fragments [J]. Int J Pept Protein Rcs,1983,21(1):93 99.
  • 3Amarapurkar D, Das H S. Thymosin alpha in the treatment of chronic hepatitis B: an uncontrolled open-label trial[J]. Indian J Gastroenterol,2002,21(2): 59-61.
  • 4Saruc M,Yuceyar H, Kucukmetin N, et al. Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey[J]. Hepatogastroenterology, 2002,49 (45): 798-802.
  • 5Lau G K, Nanji A, Hou J, et al. Thymosin alpha 1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase[J]. Viral Hepat, 2002, 9(4):280-287.
  • 6Andreone P, Cursaro C, Gramenzi A, et al. In vitro effect of thymosin-alphal and interferon-alpha on Th1 and Th2 cy tokine synthesis in patients with chronic hepatitis C[J]. J Viral Hepat. 2001,8:194-201.
  • 7Moscarella S, Buzzelli G, Romanelli R G, et al. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: prelim inary results[J]. Liver, 1998,18(5) :366-369.
  • 8Beuth J, Schierholz J M,Mayer G. Thymosin alpha(1)application augments immune response and down-regulates tumor weight and organ colonization in BALB/c-mice[J]. Cancer Lett,2000,159(1): 9-13.
  • 9Silecchia G, Guarino E, Sinibadi V P, et al. Efficacy of repeated cycles of chemoimmunotherapy with thymosin alpha 1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery [J]. Cancer Immunol Immunother, 1999, 48(4):172-178.
  • 10Enrico G, Francesca P, Paola S V, et al. Thymosin α1 in combination with cytokines and chemotherapy for the treatment of cancer [J ]. International Immunopharmacology,2003,3(8):1 145-1 150.

共引文献4

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部